Regeneron ESMO IO Presentations Highlight Potential of Fianl

Presentations include initial results for an investigational combination of fianlimab (LAG-3 inhibitor) and Libtayo (PD-1 inhibitor) in advanced n...

Related Keywords

Israel , Geneva , Genè , Switzerland , Canada , Brazil , Georged Yancopoulos , Regeneron Velocimmune , Regeneron Pharmaceuticals , Regeneron Pharmaceuticals Inc , Regeneron Genetics Center , Drug Administration , Clinical Sciences , Regeneron Velocimmune Technology , Nasdaq , Exchange Commission , Oncology Esmo Io Congress , European Society For Medical Oncology Immuno , European Union , European Society , Medical Oncology Immuno , Israel Lowy , Senior Vice President , Nonproprietary Naming , Biological Products Guidance , Indications Libtayo , Prescribing Information , Chief Scientific Officer George , Regeneron Genetics , Looking Statements , Product Candidates ,